ArticleSurgical endoscopy2022
Endoscopic sleeve gastroplasty (ESG) for morbid obesity: how effective is it?
Article in Surgical endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Short-Term Versus Long-Term Efficacy of Endoscopic Sleeve Gastroplasty in 8880 Obese Patients: A Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Outcomes of Endoscopic Sleeve Gastroplasty: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- IFSO Bariatric Endoscopy Committee Evidence-Based Review and Position Statement on Endoscopic Sleeve Gastroplasty for Obesity Management.Obesity surgery · 2024Pooled it
- Endoscopic sleeve gastroplasty video annotation: analysis of the learning curve of three annotators to achieve procedure proficiency.International journal of surgery (London, England) · 2026Article
- Dynamic magnetic resonance imaging evaluation of stomach geometry modifications after endoscopic sleeve gastroplasty.Surgical endoscopy · 2026Article
- Intragastric Balloon Therapy: Short-Term Gains and the Quest for Long-Term Success.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.Digestive diseases and sciences · 2025Article
- Endoscopic sleeve gastroplasty video assessment: do technical features influence ESG integrity and weight loss at 6 and 12 months follow-up?Surgical endoscopy · 2025Article
- Article
- Short-Term Outcomes of Laparoscopic Sleeve Gastrectomy for Weight Loss and Gastroesophageal Reflux Disease.Cureus · 2025Article
- How does sutures pattern influence stomach motility after endoscopic sleeve gastroplasty? A computational study.Updates in surgery · 2024Article
- The evolution and current state of bariatric endoscopy in Western countries.Clinical endoscopy · 2024Review
- From Early to Mid-Term Results of Endoscopic Sleeve Gastroplasty: A Retrospective Analysis of a Bariatric Center.Obesity surgery · 2024Article
- Machine learning models to predict success of endoscopic sleeve gastroplasty using total and excess weight loss percent achievement: a multicentre study.Surgical endoscopy · 2024Article
- Overview on the endoscopic treatment for obesity: A review.World journal of gastroenterology · 2023Review
- Endoscopic sleeve gastroplasty in class III obesity: Efficacy, safety, and durability outcomes in 404 consecutive patients.World journal of gastrointestinal endoscopy · 2023Article
- Endoscopic Sleeve Gastroplasty: A Safe Bariatric Intervention for Class III Obesity (BMI > 40).Obesity surgery · 2023Article
- Endoscopic sleeve gastroplasty: early results of a minimally invasive procedure in patients with obesity.Surgical endoscopy · 2023Article
- Review
- Safety and early efficacy of endoscopic sleeve gastroplasty (ESG) for obesity in a multi-ethnic Asian population in Singapore.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionESG is an effective treatment for classes I and II obesity. However, the benefit of ESG in patients with morbid obesity (BMI ≥ 40 kg/m
methodsWe reviewed 484 patient records and identified 435 patients (class I: 105, class II: 169, class III: 161) who underwent ESG at our unit between May 2013 and March 2020. We compared their total body weight loss (%TBWL) and safety over 1 year. We used a linear mixed model (LMM) to analyse repeated measures of weight loss outcomes at 3, 6, 9, and 12 months for comparison between the three BMI groups.
resultsAmong the 435 patients, 396 patients (class I: 99, class II: 151, class III: 146) completed 6 months, and 211 patients reached 1 year (class I: 50, class II: 77, class III: 84). There was no difference in age between the groups. In LMM analysis, adjusting for age and sex, we found ESG had a significantly higher TBWL, %TBWL, and BMI decline in class III compared to classes I and -II obesity at all time points (p < 0.001). The adjusted mean %TBWL at 1 year with classes I, -II, and -III obesity was 16.5%, 18.2%, and 20.5%, respectively. The overall complication rate and the hospital stay was identical in the three groups.
conclusionESG induced significant weight loss in all classes of obesity. In class III obesity, the weight loss achieved was significantly higher at 1 year. In patients declining or unsuitable for surgery, ESG could be considered as an alternative treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.